Related Experiment Video
Updated: Aug 11, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulant therapy after acute myocardial infarction
1McMaster University, Hamilton, Ontario, Canada.
The American Journal of Cardiology
|February 2, 1990
Summary
High-dose heparin significantly reduced left ventricular mural thrombosis in acute myocardial infarction patients. Monitoring heparin levels ensures treatment effectiveness without increasing bleeding risks.
Area of Science:
- Cardiology
- Thrombosis Research
- Pharmacology
Background:
- Anticoagulant therapy use in acute myocardial infarction (AMI) patients remains debated due to conflicting early study results.
- Reanalysis of historical data suggests anticoagulation offers significant clinical benefits for AMI patients.
- Left ventricular mural thrombosis is a common AMI complication, increasing the risk of systemic emboli.
Purpose of the Study:
- To evaluate the efficacy of low- and high-dose calcium heparin in preventing left ventricular mural thrombosis post-AMI.
- To assess if reduced mural thrombosis incidence correlates with a lower risk of systemic embolic complications.
- To determine optimal anticoagulation strategies through monitoring plasma heparin levels and anticoagulant response.
Main Methods:
- A 10-day in-hospital study comparing low-dose versus high-dose calcium heparin in AMI patients.
- Two-dimensional echocardiography utilized for the detection of left ventricular mural thrombi.
- Analysis of plasma heparin concentrations and activated partial thromboplastin times in relation to thrombus development.
Main Results:
- The incidence of left ventricular mural thrombosis was significantly lower in the high-dose heparin group compared to the low-dose group.
- In patients who developed mural thrombosis within the high-dose group, lower plasma heparin levels and shorter activated partial thromboplastin times were observed.
- No significant differences were found between the high- and low-dose groups regarding bleeding complications, nonhemorrhagic strokes, or mortality.
Conclusions:
- High-dose heparin therapy effectively reduces left ventricular mural thrombosis in acute myocardial infarction patients.
- Monitoring plasma heparin levels and anticoagulant response is crucial for maximizing treatment efficacy.
- The study supports the use of anticoagulants in AMI, with high-dose heparin showing promise in preventing embolic complications without increasing adverse events.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...